The DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.
Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments
Abstract
Glutamate and gamma-amino butyric acid (GABA) systems are emerging as targets for development of medications for mood disorders. There is increasing preclinical and clinical evidence that antidepressant drugs directly or indirectly reduce N-methyl-D-aspartate glutamate receptor function. Drugs that reduce glutamatergic activity or glutamate receptor-related signal transduction may also have antimanic effects. Recent studies employing magnetic resonance spectroscopy also suggest that unipolar, but not bipolar, depression is associated with reductions in cortical GABA levels. Antidepressant and mood-stabilizing treatments also appear to raise cortical GABA levels and to ameliorate GABA deficits in patients with mood disorders. The preponderance of available evidence suggests that glutamatergic and GABAergic modulation may be an important property of available antidepressant and mood-stabilizing agents. Future research will be needed to develop and evaluate new agents with specific glutamate and GABA receptor targets in the treatment of mood disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mood disorders have been associated with abnormalities of serotonergic, dopaminergic, noradrenergic, cholinergic, glutamatergic, GABAergic, glucocorticoid, and peptidergic function (Drevets et al, 2007;Nestler and Carlezon, 2006;Krystal et al, 2002;Gold et al, 2002).”
From Neurocircuitry of Mood Disorders (2010) · cites this paper as Krystal et al, 2002
In the citing paper
“antidepressant and mood-stabilizing drugs which have diverse primary pharmacological actions generally reduce NMDA receptor sensitivity and/or transmission, and many of these agents increase GABA levels or transmission (Krystal et al. 2002; Paul and Skolnick 2003).”
From Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression (2008) · cites this paper as Krystal et al. 2002
In the citing paper
“Ketamine (an NMDA receptor antagonist) affects fast excitatory glutamate transmission, increases release of brain-derived neurotrophic factor, and stimulates synaptogenesis (7).”
Citations
Cites
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Self-citationKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Self-citationArzneimittelforschung: Eine Zukunftsoption für Ärzte?
Bethke, T. D. (2012) · Der Pneumologe · doi:10.1007/s10405-012-0601-3 · Cited by 3,261
Subgenual prefrontal cortex abnormalities in mood disorders
Drevets, W. C., Price, J. L., Simpson, J. R., Todd, R. D., Reich, T., Vannier, M., & Raichle, M. E. (1997) · Nature · doi:10.1038/386824a0 · Cited by 2,693
Mayberg, H. S., Liotti, M., Brannan, S. K., McGinnis, S., Mahurin, R. K., Jerabek, P. A., Silva, J. A., Tekell, J. L., Martin, C. C., Lancaster, J. L., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.5.675 · Cited by 2,416
Glucocorticoids and Hippocampal Atrophy in Neuropsychiatric Disorders
Sapolsky, R. M. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.10.925 · Cited by 2,016
Hippocampal atrophy in recurrent major depression
Sheline, Y. I., Wang, P. W., Gado, M. H., Csernansky, J. G., & Vannier, M. W. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.3908 · Cited by 1,932
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Hippocampal Volume Reduction in Major Depression
Bremner, J. D., Narayan, M., Anderson, E. R., Staib, L. H., Miller, H. L., & Charney, D. S. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.115 · Cited by 1,670
Self-citationGlial reduction in the subgenual prefrontal cortex in mood disorders
Öngür, D., Drevets, W. C., & Price, J. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13290 · Cited by 1,525
Research works printed but not linked: 9
- Delgado PL . Depression: the case for a monoamine deficiency J Clin Psychiatry 2000 61 (Suppl 6): 7–11
- Cappiello A, Charney DS, Berman R et al. NMDA receptor function in major depression Biol Psychiatry 1997 41: 45S
- Mason GF, Haga K, Appel M et al. Measuring cortical GABA levels and neurotransmitter turnover with 1H-MRS and 13C-MRS Biol Psychiatry 2001 49: 148S
- Krystal JH, Petrakis IL, D'Souza DC, Trevisan L, Krasnicki S, Charney DS . Interactive effects of high dose intravenous glycine and oral D-cycloserine in healthy human subjects Biol Psychiatry 1997 41 (Suppl): 23S
- Blumberg HP, Leung HC, Wexler B et al. Ventral prefrontal dysfunction in bipolar disorder: an fMRI study Biol Psychiatry 2001 49: 26S
- Krystal JH, Belger A, Kirino E, Gore J, McCarthy G . Ketamine effects on the cortical processing of novelty in humans assessed with fMRI Soc Neurosci Abstr 1998 24: 104.7
- Newcomer JW, Farber NB, Selke G, Melson AK, Jevtovic-Todorovic V, Olney JW . Guanabenz effects on NMDA antagonist-induced mental symptoms in human Soc Neurosci Abstr 1998 24: 211.2
- Lahti AC, Weiler MA, Parwani A et al. Blockade of ketamine-induced psychosis with olanzepine Schizophr Res 1999 36: 310
- Epperson CN, Mason G, Rothman DR, Sanacora G, Krystal JH . GABA dysregulation in premenstrual dysphoric disorder Soc Neurosci Abstr 1999 25: 2227
Cited by
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
The Wellcome Trust Case Control Consortium, Management Committee, Burton, P. R., Clayton, D. G., Cardon, L. R., Craddock, N., Deloukas, P., Duncanson, A., Kwiatkowski, D. P., McCarthy, M. I., et al. (2007) · Nature · doi:10.1038/nature05911 · Cited by 9,442
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationDrevets, W. C., Price, J. L., & Furey, M. L. (2008) · Brain Structure and Function · doi:10.1007/s00429-008-0189-x · Cited by 2,241
“Moreover, antidepressant and mood-stabilizing drugs which have diverse primary pharmacological actions generally reduce NMDA receptor sensitivity and/or transmission, and many of these agents increase GABA levels or transmission (Krystal et al. 2002; Paul and Skolnick 2003).”
BackgroundCryan, J. F., Mombereau, C., & Vassout, A. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.009 · Cited by 1,674
Metadata
- Authors
- Krystal, J. H., Sanacora, G., Blumberg, H., Anand, A., Charney, D. S., Marek, G., Epperson, C. N., Goddard, A., & Mason, G. F.
- Affiliations
- Yale University (US)
- Corresponding author
- Krystal, J H
- Venue
- Molecular Psychiatry
- Published
- 2002-01-01
- Volume
- 7
- Issue
- S1
- Pages
- S71-S80
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2023866167
- Cited by
- 553
- References
- 124
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 14 · 2023: 17 · 2022: 17 · 2021: 49 · 2020: 21 · 2019: 16 · 2018: 20 · 2017: 17 · 2016: 29 · 2015: 19 · 2014: 25 · 2013: 31 · 2012: 28
- FWCI
- 2.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (K23MH001830)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- glutamate, GABA, antidepressants, mood stabilizers, mood disorders, depression, mania, NMDA receptor, glutamatergic signaling, bipolar disorder, major depressive disorder, therapeutic target
- MeSH terms
- Antidepressive Agents, gamma-Aminobutyric Acid, Humans, Models, Neurological, Synaptic Transmission, Glutamic Acid, Mood Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. https://app.cochat.ai/papers/10.1038/sj.mp.4001021
- The paper
- Krystal, J. H., Sanacora, G., Blumberg, H., Anand, A., Charney, D. S., Marek, G., Epperson, C. N., Goddard, A., & Mason, G. F. (2002). Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Molecular Psychiatry. https://doi.org/10.1038/sj.mp.4001021
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.